Search results for " metastasis"

showing 10 items of 623 documents

BRAF(V600E) MUTATION AND THE BIOLOGY OF PAPILLARY THYROID CANCER

2008

BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers. We evaluated the relationship between BRAF((V600E)) and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF((V600E)) was investigated in a series of 323 PTCs diagnosed in 2002-2005. The correlation between clinicopathological tumor, host, and environmental characteristics and the presence of BRAF((V600E)) were evaluated by both univariate and multivariate analyses. BRAF((V600E)) was found in 38.6% PTCs, with a 52% frequency in the classical PTCs and 26.4% in the tall cell variant. Univariate analysis indi…

MaleCancer Researchendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.disease_causethyroidPapillary thyroid cancerSettore MED/13 - EndocrinologiaImmunoenzyme TechniquesEndocrinologythyroid cancerskin and connective tissue diseasesSicilyMicrodissectionBRAF(V600E)Univariate analysisMutationGeographyReverse Transcriptase Polymerase Chain ReactionThyroidBRAF V600; Papillary Thyroid CancerMiddle Agedhumanitiesmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyLymphatic MetastasisDisease ProgressionFemaleMicrodissectionProto-Oncogene Proteins B-rafPapillary thyroid cancer BRAF(V600E) thyroid thyroid cancerBRAF V600BiologyThyroid carcinomamedicineCarcinomaHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsneoplasmsDNA PrimersLasersPapillary thyroid cancer BRAFmedicine.diseaseCarcinoma Papillarydigestive system diseasesMutationCancer researchV600EFollow-Up StudiesPapillary Thyroid Cancer
researchProduct

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

2006

Recent studies have highlighted that Activin A, a member of the transforming growth factor-beta (TGF-beta) superfamily, may be involved in the regulation of osteoblastic activity and in osteoclast differentiation. Therefore, we have investigated the clinical significance of its circulating levels in patients with bone metastasis. Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with breast cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15 female patients with age-related osteoporosis (OP), in 20 patients with benign prostatic hypertrophy (BPH) and in 48 registered healthy b…

MaleCancer Researchmedicine.medical_specialtyBone diseaseOsteoporosisProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsActivin A; Benign prostatic hypertrophy; Bone metastasis; Breast cancer; Neoplasm; > Osteoporosis; Prostate cancer; Transforming growth factor ¦Â; Tumor markersSensitivity and SpecificityGastroenterologyProstate cancerBreast cancerBreast cancerOsteoclastInternal medicineBiomarkers TumormedicineHumansAgedAged 80 and overHematologyProstate cancerbusiness.industryOsteoporosiProstatic NeoplasmsBone metastasisCancerGeneral MedicineMiddle AgedActivin ATransforming growth factor ¦Âmedicine.diseaseBenign prostatic hypertrophyActivinsmedicine.anatomical_structureEndocrinologyOncologyBone metastasiTumor markersOsteoporosisNeoplasmFemalebusiness
researchProduct

Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic canc…

1996

Two doses of megestrol acetate (MA) have been prospectively compared in a random fashion as treatment for cancer-related anorexia-cachexia syndrome (ACS) in 122 patients with progressive soft tissue sarcoma, colorectal, lung, head and neck and renal cancer resistant to systemic chemotherapy. After 30 days of MA, 55% of patients receiving MA at 160 mg day-1 reported an increase in appetite, 27% of patients no variation and 18% complained of a decrease in appetite. Patients treated with MA at 320 mg day-1 reported an increase in appetite in 68% of cases, a stabilisation in 20% of cases and a decrease in 12%. Although an increase in appetite was more frequently observed in patients receiving M…

MaleCancer Researchmedicine.medical_specialtyCachexiamedia_common.quotation_subjectAppetiteAnorexiaGastroenterologyCachexiachemistry.chemical_compoundWeight lossNeoplasmsInternal medicinemedicineHumansProspective StudiesNeoplasm MetastasisProspective cohort studyAgedmedia_commonDose-Response Relationship DrugPerformance statusbusiness.industryMegestrol AcetateBody WeightAppetiteMegestrolSyndromeMiddle Agedmedicine.diseaseAnorexiaSurgeryOncologychemistryMegestrolMegestrol acetateFemalemedicine.symptombusinessResearch Articlemedicine.drugBritish Journal of Cancer
researchProduct

Serum follistatin in patients with prostate cancer metastatic to the bone

2010

The clinical significance of circulating fol- listatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M?) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy sub- jects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Converse…

MaleCancer Researchmedicine.medical_specialtyFollistatinBone diseaseSettore MED/06 - Oncologia MedicaBone metastasis cancer follistatin prostate cancer transforming growth factor beta tumor markersBone Neoplasmsurologic and male genital diseasesGastroenterologySensitivity and SpecificityProstate cancerInternal medicineMedicineHumansClinical significanceAgedHematologybusiness.industryCancerBone metastasisProstatic NeoplasmsGeneral MedicineHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseActivinsProstate-specific antigenEndocrinologyOncologySettore BIO/14 - Farmacologiabusiness
researchProduct

Are the recommendations of the French consensus conference on the management of colon cancer followed up?

2006

The aim of this study was to determine how the guidelines published after this conference have spread. Pretherapeutic evaluation and treatment were assessed for all colon cancers diagnosed in a well-defined French population in 2000. Patients were classified either as managed according to the recommendations, or as undermanaged or overmanaged. Outside the emergency context, pretherapeutic work-up was classified as in conformity with the consensus in 48.0% of the cases, as undervalued in 21.9% and as overvalued in 30.1%. The resection rate at 90% was not far from the optimum. Pathological data allowed us to classify nearly all cases according to the tumour node metastasis classification; how…

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisHealth Planning GuidelinesEpidemiologyColorectal cancerConsensus Development Conferences as TopicPopulationColonoscopyContext (language use)Antineoplastic AgentsMedicineHumansNeoplasm MetastasiseducationAgedNeoplasm StagingAged 80 and overeducation.field_of_studyTumour node metastasismedicine.diagnostic_testbusiness.industryGeneral surgeryPublic Health Environmental and Occupational HealthConsensus conferenceGuidelineColonoscopymedicine.diseaseSurgeryOncologyColonic NeoplasmsFemaleFranceGuideline AdherencebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck

1992

A group of 60 patients with advanced head/neck cancer were treated with high-dose folinic acid (500 mg/m-2/week-1) plus 5-fluorouracil (400 mg/m-2/week-1 on day 1, and cisplatin (20 mg/m-2/week-1) 24 h after folinic acid infusion was completed. Out of 55 evaluable patients, 10 patients (18%) experienced a complete response with a mean duration of 11.4+ months, 25 patients had a partial response (45%) of 6.7+ months, 6 patients (11%) showed a stabilization of 4.8+ months, and 14 (25%) progressed. The overall response rate was 63.6% (95% confidence limits 56.5%-69.5%). Patients pretreated with radiotherapy had a 67% overall response rate, while those pretreated with chemotherapy showed a 54% …

MaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentCystadenocarcinomaLeucovorinAdenocarcinomaGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisChemotherapyLeukopeniabusiness.industryCarcinomaCancerGeneral MedicineMiddle Agedmedicine.diseaseRadiation therapyOncologyHead and Neck NeoplasmsFluorouracilAnesthesiaCarcinoma Squamous CellVomitingFemaleFluorouracilCisplatinmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.

2008

The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from breast cancer (BCa) or prostate cancer (PCa). Additional studies were also performed in these patients to assess the effects of zoledronic acid (ZA) administration on the circulating levels of these molecules. Mean IL-6 and Cyst C serum concentrations were signifi- cantly increased in BCa patients and in patients with primary osteoporosis (PU) compared to healthy subjects (HS). However, Cyst C, but not IL-6, resulted significantly more elevated in BCa patients t…

MaleCancer Researchmedicine.medical_specialtyPathologyBone diseasemedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsZoledronic AcidGastroenterologyProstate cancercancer metastatic bone disease cystatin cInternal medicineBiomarkers TumormedicineHumansCystCystatin CAgedAged 80 and overBone Density Conservation AgentsDiphosphonatesbiologyInterleukin-6business.industryImidazolesProstatic NeoplasmsCancerBone metastasisHematologyGeneral MedicineMiddle AgedProstate-Specific AntigenBisphosphonatemedicine.diseaseZoledronic acidROC CurveOncologyCystatin Cbiology.proteinOsteoporosisFemalebusinessmedicine.drug
researchProduct

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1994

BACKGROUND The influence of DNA content on prognosis in stomach cancer has been investigated rarely, and the results are controversial. METHOD The prognostic relevance of the DNA content and histomorphologic parameters was evaluated in 41 patients after resection of pancreatic cancer. RESULTS In the univariate analysis, the DNA content, tumor size, lymph node status, tumor stage, nuclear grade, and type of resection had a statistically significant influence on the prognosis. No association was found between the DNA content and the histomorphologic features. Apart from the operative procedure, the DNA content was the strongest indicator of prognosis in the multivariate analysis. CONCLUSIONS …

MaleCancer Researchmedicine.medical_specialtyPathologyPancreatic diseaseMultivariate analysisGastroenterologyPolyploidyPancreatectomyText miningPancreatic cancerInternal medicinemedicineHumansStomach cancerLymph nodeNeoplasm StagingCell NucleusUnivariate analysisbusiness.industryDNA NeoplasmPrognosismedicine.diseaseDiploidyPancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisMultivariate AnalysisLymph Node ExcisionFemalePancreasbusinessFollow-Up StudiesCancer
researchProduct

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.

2018

BACKGROUND We examined the expression of CD200, a ligand of immune tolerance, in transitional cell carcinoma of the human bladder (TCC). MATERIALS AND METHODS CD200 was analyzed by immunohistochemistry (IHC) in 90 patients with suspected TCC lesions of the bladder. Expression of CD200 was exemplarily validated by quantitative reverse transcription polymerase chain reaction and western blot analysis. RESULTS CD200 was detectable at mRNA and protein levels in TCC homogenate and TCC cell lines (T24, UMUC3). TCC tissues showed significantly higher CD200 expression (p<0.005) than normal bladder tissues. CD200 signals were also higher in metastasized compared to localized TCC (p<0.05). CD200 was …

MaleCancer Researchmedicine.medical_treatmenturologic and male genital diseasesMetastasis03 medical and health sciences0302 clinical medicineWestern blotAntigens CDmedicineBiomarkers TumorHumansRNA MessengerRNA NeoplasmNeoplasm MetastasisneoplasmsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancermedicine.diagnostic_testbusiness.industryCell DifferentiationGeneral MedicineImmunotherapymedicine.diseasefemale genital diseases and pregnancy complicationsImmune checkpointNeoplasm ProteinsReverse transcription polymerase chain reactionTransitional cell carcinomaOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleTumor EscapeNeoplasm Gradingbusiness030215 immunologyAnticancer research
researchProduct